Literature DB >> 9040736

Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies.

A Schenone1, L Nobbio, P Mandich, E Bellone, M Abbruzzese, F Aymar, G L Mancardi, A J Windebank.   

Abstract

Hereditary neuropathy with liability to pressure palsies (HNPP) is associated with a deletion in chromosome 17p11.2, including the gene for the peripheral myelin protein 22 (PMP-22). Because of the proposal that a decreased dosage of the PMP-22 gene was the cause of HNPP, we evaluated sural nerves from eight patients with the 17p11.2 deletion and from five normal controls. The relative amount of PMP-22 mRNA was significantly lower in HNPP patients compared with normal controls (p < 0.02) using a semiquantitative reverse transcriptase-polymerase chain reaction. There was no significant decrease of Pzero mRNA. Sural nerves from HNPP patients showed normal immunostaining with monoclonal antibodies against PMP-22, Pzero, and myelin basic protein, and only rare myelinated fibers, classified as "tomacula," showed a patchy staining of the compact myelin with monoclonal antibody against PMP-22. The significant underexpression of PMP-22 mRNA in HNPP patients compared with normal controls demonstrates that a decreased dosage of the PMP-22 gene is the most likely pathogenetic mechanism in HNPP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040736     DOI: 10.1212/wnl.48.2.445

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Hereditary neuropathy with liability to pressure palsy combined with suspected schwannomas of the peroneal and radial nerves.

Authors:  Masaki Ohyagi; Nobuo Sanjo; Takanori Yokota; Hidehiro Mizusawa
Journal:  J Neurol       Date:  2011-10-27       Impact factor: 4.849

Review 2.  Inherited focal, episodic neuropathies: hereditary neuropathy with liability to pressure palsies and hereditary neuralgic amyotrophy.

Authors:  Phillip F Chance
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

3.  Development of early postnatal peripheral nerve abnormalities in Trembler-J and PMP22 transgenic mice.

Authors:  A M Robertson; C Huxley; R H King; P K Thomas
Journal:  J Anat       Date:  1999-10       Impact factor: 2.610

Review 4.  Animal models for inherited peripheral neuropathies.

Authors:  R Martini
Journal:  J Anat       Date:  1997-10       Impact factor: 2.610

5.  PMP22 expression in dermal nerve myelin from patients with CMT1A.

Authors:  Istvan Katona; Xingyao Wu; Shawna M E Feely; Stephanie Sottile; Carly E Siskind; Lindsey J Miller; Michael E Shy; Jun Li
Journal:  Brain       Date:  2009-05-15       Impact factor: 13.501

6.  A novel PMP22 mutation Ser22Phe in a family with hereditary neuropathy with liability to pressure palsies and CMT1A phenotypes.

Authors:  Kleopas A Kleopa; Domna-Maria Georgiou; Paschalis Nicolaou; Pantelitsa Koutsou; Eleftherios Papathanasiou; Theodoros Kyriakides; Kyproula Christodoulou
Journal:  Neurogenetics       Date:  2004-06-17       Impact factor: 2.660

7.  An abnormal mRNA produced by a novel PMP22 splice site mutation associated with HNPP.

Authors:  E Bellone; P Balestra; G Ribizzi; A Schenone; G Zocchi; E Di Maria; F Ajmar; P Mandich
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-30       Impact factor: 10.154

8.  A novel case of concurrent occurrence of demyelinating-polyneuropathy-causing PMP22 duplication and SOX10 gene mutation producing severe hypertrophic neuropathy.

Authors:  Nozomu Matsuda; Koushi Ootsuki; Shunsuke Kobayashi; Ayaka Nemoto; Hitoshi Kubo; Shin-Ichi Usami; Kazuaki Kanani
Journal:  BMC Neurol       Date:  2021-06-25       Impact factor: 2.474

Review 9.  PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies.

Authors:  Barbara W van Paassen; Anneke J van der Kooi; Karin Y van Spaendonck-Zwarts; Camiel Verhamme; Frank Baas; Marianne de Visser
Journal:  Orphanet J Rare Dis       Date:  2014-03-19       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.